DOCSLIB.ORG

Angiogenic Properties of NK Cells in Cancer and Other Angiogenesis-Dependent Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Angiogenic Properties of NK Cells in Cancer and Other Angiogenesis-Dependent Diseases cells Review Angiogenic Properties of NK Cells in Cancer and Other Angiogenesis-Dependent Diseases Dorota M. Radomska-Le´sniewska 1, Agata Białoszewska 1,* and Paweł Kami ´nski 2 1 Center for Biostructure Research, Department of Histology and Embryology, Medical University of Warsaw, 02-004 Warsaw, Poland; [email protected] 2 Department of Gynecology and Gynecological Oncology, Military Institute of Medicine, 04-349 Warsaw, Poland; [email protected] * Correspondence: [email protected] Abstract: The pathogenesis of many serious diseases, including cancer, is closely related to distur- bances in the angiogenesis process. Angiogenesis is essential for the progression of tumor growth and metastasis. The tumor microenvironment (TME) has immunosuppressive properties, which con- tribute to tumor expansion and angiogenesis. Similarly, the uterine microenvironment (UME) exerts a tolerogenic (immunosuppressive) and proangiogenic effect on its cells, promoting implantation and development of the embryo and placenta. In the TME and UME natural killer (NK) cells, which otherwise are capable of killing target cells autonomously, enter a state of reduced cytotoxicity or anergy. Both TME and UME are rich with factors (e.g., TGF-β, glycodelin, hypoxia), which support a conversion of NK cells to the low/non-cytotoxic, proangiogenic CD56brightCD16low phenotype. It is plausible that the phenomenon of acquiring proangiogenic and low cytotoxic features by NK cells is not only limited to cancer but is a common feature of different angiogenesis-dependent diseases (ADDs). In this review, we will discuss the role of NK cells in angiogenesis disturbances associated Citation: Radomska-Le´sniewska, D.M.; with cancer and other selected ADDs. Expanding the knowledge of the mechanisms responsible Białoszewska, A.; Kami´nski,P. for angiogenesis and its disorders contributes to a better understanding of ADDs and may have Angiogenic Properties of NK therapeutic implications. Cells in Cancer and Other Angiogenesis-Dependent Diseases. Keywords: NK cells; decidual NK cells; angiogenesis; proangiogenic factors; tumor microenvironment; Cells 2021, 10, 1621. https://doi.org/ endometriosis; rheumatoid arthritis; VEGF; TGF-β; hypoxia 10.3390/cells10071621 Academic Editor: Alessandro Poggi 1. Introduction Received: 30 May 2021 Angiogenesis, a new blood vessel formation from preexisting vasculature, is a normal Accepted: 26 June 2021 Published: 29 June 2021 and vital process in growth and development. Physiologically, angiogenesis regulates embryogenesis, the menstrual cycle, wound healing, and the formation of granulation Publisher’s Note: MDPI stays neutral tissue [1]. with regard to jurisdictional claims in Disturbances in neovascularization can lead to serious health consequences since the published maps and institutional affil- pathogenesis of many severe conditions is closely related to angiogenic disorders. These iations. conditions are called angiogenesis-dependent diseases (ADDs) and are characterized by a disturbed formation of new vessels, which affects their organization, structure, and function [2]. ADDs comprise conditions with excessive pathological angiogenesis, such as cancer, some eye diseases (e.g., age-related macular degeneration [AMD]), or chronic inflammatory disorders (e.g., rheumatoid arthritis [RA], psoriasis) and diseases with Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. insufficient angiogenesis (e.g., diabetes mellitus, stroke, atherosclerosis, hypertension, or This article is an open access article ischemic heart disease) [2,3]. distributed under the terms and Angiogenesis is a complex and multi-stage process usually induced by hypoxia, which conditions of the Creative Commons stimulates hypoxia-inducible factor-1 (HIF-1) leading to gene expression for proangiogenic Attribution (CC BY) license (https:// factors, such as the most powerful stimulator, vascular endothelial growth factor (VEGF), creativecommons.org/licenses/by/ and its receptor VEGFR-1/FLT-1 (Figure1)[ 4,5]. Many different kinds of cells participate 4.0/). in the regulation of angiogenesis, mainly by secreting various factors which control this Cells 2021, 10, 1621. https://doi.org/10.3390/cells10071621 https://www.mdpi.com/journal/cells Cells 2021, 10, x FOR PEER REVIEW 2 of 26 Cells 2021, 10, 1621 2 of 25 cells participate in the regulation of angiogenesis, mainly by secreting various factors whichprocess control (Figure this1). process The diverse (Figure group 1). T ofhe angiogenesis diverse group regulating of angiogenesis cells includes regulating natural cells includeskiller (NK) natural cells, whichkiller (NK) are innate cells, lymphocyteswhich are innate (generally lymphocytes cytotoxic (generally ones) that cyt provideotoxic oprotectionnes) that provide against protection viral infections against and viral tumor infections metastasis. and tumor NK cells metastasis. also modulate NK cells other also modulateaspects of other the immune aspects systemof the i throughmmune thesystem rapid through production the rapid of numerous production cytokines of numer- and ouschemokines. cytokines Out and of chemokines. the broad spectrum Out of the of NK broad cell spectrum subpopulations, of NK somecell subpopul were shownations to, soaffectme were angiogenesis shown to by affect VEGF, angiogenesis placenta growth by VEGF, factor placenta (PlGF), growth interleukin factor (IL)-8/CXCL8, (PlGF), inter- leukinIL-10, angiopoietin(IL)-8/CXCL8 (Ang)-1,, IL-10, andangiopoietin Ang-2 production (Ang)-1, [ 6and]. There Ang is-2 aproduction unique subset [6]. ofThere decidual is a uniqueNK (dNK) subset cells of known decidual to participateNK (dNK) incells vascularization known to participat during embryonice in vascularization and placental dur- ingdevelopment embryonic [ 7and]. Recently, placenta al d similarevelopment nurturing [7]. Recently, activity of a NKsimilar cells nurturing has been activity described of NKunder cells pathological has been described conditions, under predominantly pathological in different conditions, types predominantly of cancer, which in indicatesdifferent typethe relevances of cancer of, which NK cells indicates in the developmentthe relevance of ADDsNK cells [8 –in13 the]. A development better understanding of ADDs [8of– the13]. mechanismsA better understanding in which NK of cellsthe mechanisms regulate angiogenesis in which NK and cells its disordersregulate a mayngiogen be ofe- sistherapeutic and its disorders significance. may In be this of article,therapeutic we will sign summarizeificance. In the this current article, body we ofwill knowledge summa- rizeon NK the cell current biology, body with of knowledge a special focus on NK on the cell angiogenic biology, with properties a special of focus NK cells on inthe cancer angi- ogenicand other properties ADDs. of NK cells in cancer and other ADDs. Figure 1. StagesStages of of t thehe angiogenesis angiogenesis process process and its regulation. New New bl bloodood vessel vessel formation formation is is upregulated upregulated by by hypoxia, hypoxia, which stimulatesstimulates hypoxia-induciblehypoxia-induciblefactor-1 factor-1 (HIF-1) (HIF-1) leading leading to to the the vascular vascular endothelial endothelial growth growth factor factor (VEGF) (VEGF) expression. expres- sion. VEGF, fibroblast growth factor (FGF), transforming growth factor (TGF), platelet-derived growth factor (PDGF), VEGF, fibroblast growth factor (FGF), transforming growth factor (TGF), platelet-derived growth factor (PDGF), hepatocyte hepatocyte growth factor (HGF), placenta growth factor (PlGF), angiogenin, angiopoietin (Ang)-1, interleukin (IL)-8, IL- growth6, IL-17, factor matrix (HGF), metalloproteinases placenta growth (MMPs), factor (PlGF), and tumor angiogenin, necrosis angiopoietin factor (TNF) (Ang)-1, stimulate interleukin angiogenesis. (IL)-8, IL-6,Inhibitors IL-17, o matrixf neo- metalloproteinasesvascularization include (MMPs), angiostatin, and tumor endostatin, necrosis factor thrombospondin, (TNF) stimulate tissue angiogenesis. inhibitors Inhibitors of matrix of metalloproteinases neovascularization (TIMP), include angiostatin,interferon (IFN endostatin,)-α, IL-10, thrombospondin, IL-12, IL-18, IL-23, tissue IL-25, inhibitors IL-27, and of matrixAng-2. metalloproteinases The various kinds (TIMP),of cells participating interferon (IFN)- in theα, IL-10,regu- IL-12,lation IL-18,of angiogenesis, IL-23, IL-25, mainly IL-27, andby secreting Ang-2. The stim variousulatory kinds and/or of cellsinhibitory participating factors, in include the regulation endothelial of angiogenesis, cells, macrophages mainly by(MΦ) secreting, mast cells, stimulatory fibroblasts, and/or CD56 inhibitory+CD16- natural factors, killer include (NK) endothelial cells, T cells, cells, neutrophils, macrophages basophils, (MF), masteosinophils, cells, fibroblasts, and den- CD56dritic +cellsCD16 (DCs)− natural [7,14 killer–18]. (NK) cells, T cells, neutrophils, basophils, eosinophils, and dendritic cells (DCs) [7,14–18]. 2. NK NK Cell Cell Biology NK cells constituteconstitute upup toto 15%15% of of circulating circulating lymphocytes lymphocytes and and can can be be found found in variousin vari- ousorgans organs and and tissues. tissues. They They are aare subset a subset of a heterogeneousof a heterogeneous family family of innate of innate lymphoid lymphoid cells cells(ILCs) (ILCs) and originate and originate from commonfrom common lymphoid lymphoid progenitors progenitors which derivewhich fromderive
Load more

Recommended publications
  • CD81 Antibody (C-Term) Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP6631B
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 CD81 Antibody (C-term) Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP6631B Specification CD81 Antibody (C-term) - Product Information Application WB, IHC-P, FC,E Primary Accession P60033 Reactivity Human, Mouse Host Rabbit Clonality Polyclonal Isotype Rabbit Ig Antigen Region 176-203 CD81 Antibody (C-term) - Additional Information Gene ID 975 Other Names CD81 antigen, 26 kDa cell surface protein TAPA-1, Target of the antiproliferative antibody 1, Tetraspanin-28, Tspan-28, Western blot analysis of CD81 Antibody CD81, CD81, TAPA1, TSPAN28 (C-term) (Cat. #AP6631b) in mouse kidney(lane 1) and cerebellum(lane 2) tissue Target/Specificity lysates (35ug/lane). CD81 (arrow) was This CD81 antibody is generated from detected using the purified Pab. rabbits immunized with a KLH conjugated synthetic peptide between 176-203 amino acids from the C-terminal region of human CD81. Dilution WB~~1:1000 IHC-P~~1:10~50 FC~~1:10~50 Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. Storage Maintain refrigerated at 2-8°C for up to 2 Formalin-fixed and paraffin-embedded weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw human brain tissue with CD81 Antibody cycles. (C-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB Precautions staining. This data demonstrates the use of CD81 Antibody (C-term) is for research use this antibody for immunohistochemistry; Page 1/4 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 only and not for use in diagnostic or clinical relevance has not been evaluated.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • CD226 T Cells Expressing the Receptors TIGIT and Divergent Phenotypes of Human Regulatory
    The Journal of Immunology Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226 Christopher A. Fuhrman,*,1 Wen-I Yeh,*,1 Howard R. Seay,* Priya Saikumar Lakshmi,* Gaurav Chopra,† Lin Zhang,* Daniel J. Perry,* Stephanie A. McClymont,† Mahesh Yadav,† Maria-Cecilia Lopez,‡ Henry V. Baker,‡ Ying Zhang,x Yizheng Li,{ Maryann Whitley,{ David von Schack,x Mark A. Atkinson,* Jeffrey A. Bluestone,‡ and Todd M. Brusko* Regulatory T cells (Tregs) play a central role in counteracting inflammation and autoimmunity. A more complete understanding of cellular heterogeneity and the potential for lineage plasticity in human Treg subsets may identify markers of disease pathogenesis and facilitate the development of optimized cellular therapeutics. To better elucidate human Treg subsets, we conducted direct transcriptional profiling of CD4+FOXP3+Helios+ thymic-derived Tregs and CD4+FOXP3+Helios2 T cells, followed by comparison with CD4+FOXP32Helios2 T conventional cells. These analyses revealed that the coinhibitory receptor T cell Ig and ITIM domain (TIGIT) was highly expressed on thymic-derived Tregs. TIGIT and the costimulatory factor CD226 bind the common ligand CD155. Thus, we analyzed the cellular distribution and suppressive activity of isolated subsets of CD4+CD25+CD127lo/2 T cells expressing CD226 and/or TIGIT. We observed TIGIT is highly expressed and upregulated on Tregs after activation and in vitro expansion, and is associated with lineage stability and suppressive capacity. Conversely, the CD226+TIGIT2 population was associated with reduced Treg purity and suppressive capacity after expansion, along with a marked increase in IL-10 and effector cytokine production. These studies provide additional markers to delineate functionally distinct Treg subsets that may help direct cellular therapies and provide important phenotypic markers for assessing the role of Tregs in health and disease.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Flow Reagents Single Color Antibodies CD Chart
    CD CHART CD N° Alternative Name CD N° Alternative Name CD N° Alternative Name Beckman Coulter Clone Beckman Coulter Clone Beckman Coulter Clone T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells CD1a T6, R4, HTA1 Act p n n p n n S l CD99 MIC2 gene product, E2 p p p CD223 LAG-3 (Lymphocyte activation gene 3) Act n Act p n CD1b R1 Act p n n p n n S CD99R restricted CD99 p p CD224 GGT (γ-glutamyl transferase) p p p p p p CD1c R7, M241 Act S n n p n n S l CD100 SEMA4D (semaphorin 4D) p Low p p p n n CD225 Leu13, interferon induced transmembrane protein 1 (IFITM1). p p p p p CD1d R3 Act S n n Low n n S Intest CD101 V7, P126 Act n p n p n n p CD226 DNAM-1, PTA-1 Act n Act Act Act n p n CD1e R2 n n n n S CD102 ICAM-2 (intercellular adhesion molecule-2) p p n p Folli p CD227 MUC1, mucin 1, episialin, PUM, PEM, EMA, DF3, H23 Act p CD2 T11; Tp50; sheep red blood cell (SRBC) receptor; LFA-2 p S n p n n l CD103 HML-1 (human mucosal lymphocytes antigen 1), integrin aE chain S n n n n n n n l CD228 Melanotransferrin (MT), p97 p p CD3 T3, CD3 complex p n n n n n n n n n l CD104 integrin b4 chain; TSP-1180 n n n n n n n p p CD229 Ly9, T-lymphocyte surface antigen p p n p n
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • Snipa Snpcard
    SNiPAcard Block annotations Block info genomic range chr19:55,117,749-55,168,602 block size 50,854 bp variant count 74 variants Basic features Conservation/deleteriousness Linked genes μ = -0.557 [-4.065 – AC009892.10 , AC009892.5 , AC009892.9 , AC245036.1 , AC245036.2 , phyloP 2.368] gene(s) hit or close-by AC245036.3 , AC245036.4 , AC245036.5 , AC245036.6 , LILRA1 , LILRB1 , LILRB4 , MIR8061 , VN1R105P phastCons μ = 0.059 [0 – 0.633] eQTL gene(s) CTB-83J4.2 , LILRA1 , LILRA2 , LILRB2 , LILRB5 , LILRP1 μ = -0.651 [-4.69 – 2.07] AC008984.5 , AC008984.5 , AC008984.6 , AC008984.6 , AC008984.7 , AC008984.7 , AC009892.10 , AC009892.10 , AC009892.2 , AC009892.2 , AC009892.5 , AC010518.3 , AC010518.3 , AC011515.2 , AC011515.2 , AC012314.19 , AC012314.19 , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , FCAR , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL1 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL3 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 , KIR2DL4 ,
    [Show full text]
  • An NK Cell-Activating Receptor with Inhibitory Potential Mathias Faure and Eric O
    KIR2DL4 (CD158d), an NK Cell-Activating Receptor with Inhibitory Potential Mathias Faure and Eric O. Long This information is current as J Immunol 2002; 168:6208-6214; ; of September 25, 2021. doi: 10.4049/jimmunol.168.12.6208 http://www.jimmunol.org/content/168/12/6208 Downloaded from References This article cites 43 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/168/12/6208.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology KIR2DL4 (CD158d), an NK Cell-Activating Receptor with Inhibitory Potential Mathias Faure and Eric O. Long1 KIR2DL4 (CD158d) is an unusual member of the killer cell Ig-like receptor family expressed in all NK cells and some T cells. KIR2DL4 activates the cytotoxicity of NK cells, despite the presence of an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic tail.
    [Show full text]
  • The VE-Cadherin/Amotl2 Mechanosensory Pathway Suppresses Aortic InAmmation and the Formation of Abdominal Aortic Aneurysms
    The VE-cadherin/AmotL2 mechanosensory pathway suppresses aortic inammation and the formation of abdominal aortic aneurysms Yuanyuan Zhang Karolinska Institute Evelyn Hutterer Karolinska Institute Sara Hultin Karolinska Institute Otto Bergman Karolinska Institute Maria Forteza Karolinska Institute Zorana Andonovic Karolinska Institute Daniel Ketelhuth Karolinska University Hospital, Stockholm, Sweden Joy Roy Karolinska Institute Per Eriksson Karolinska Institute Lars Holmgren ( [email protected] ) Karolinska Institute Article Keywords: arterial endothelial cells (ECs), vascular disease, abdominal aortic aneurysms Posted Date: June 15th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-600069/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License The VE-cadherin/AmotL2 mechanosensory pathway suppresses aortic inflammation and the formation of abdominal aortic aneurysms Yuanyuan Zhang1, Evelyn Hutterer1, Sara Hultin1, Otto Bergman2, Maria J. Forteza2, Zorana Andonovic1, Daniel F.J. Ketelhuth2,3, Joy Roy4, Per Eriksson2 and Lars Holmgren1*. 1Department of Oncology-Pathology, BioClinicum, Karolinska Institutet, Stockholm, Sweden. 2Department of Medicine Solna, BioClinicum, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 3Department of Cardiovascular and Renal Research, Institutet of Molecular Medicine, Univ. of Southern Denmark, Odense, Denmark 4Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm,
    [Show full text]
  • Natural Killer Cell Lymphoma Shares Strikingly Similar Molecular Features
    Leukemia (2011) 25, 348–358 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic cd T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro J Iqbal1, DD Weisenburger1, A Chowdhury2, MY Tsai2, G Srivastava3, TC Greiner1, C Kucuk1, K Deffenbacher1, J Vose4, L Smith5, WY Au3, S Nakamura6, M Seto6, J Delabie7, F Berger8, F Loong3, Y-H Ko9, I Sng10, X Liu11, TP Loughran11, J Armitage4 and WC Chan1, for the International Peripheral T-cell Lymphoma Project 1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA; 2Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA; 3Departments of Pathology and Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China; 4Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 5College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA; 6Departments of Pathology and Cancer Genetics, Aichi Cancer Center Research Institute, Nagoya University, Nagoya, Japan; 7Department of Pathology, University of Oslo, Norwegian Radium Hospital, Oslo, Norway; 8Department of Pathology, Centre Hospitalier Lyon-Sud, Lyon, France; 9Department of Pathology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea; 10Department of Pathology, Singapore General Hospital, Singapore and 11Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA Natural killer (NK) cell lymphomas/leukemias are rare neo- Introduction plasms with an aggressive clinical behavior.
    [Show full text]
  • NKTR-214 2017SITC Poster-P77
    The Novel IL-2 Cytokine Immune Agonist NKTR-214 Harnesses the Adaptive and Innate Immune System for the Treatment of Solid Cancers Salah Eddine Bentebibel1, Chantale Bernatchez1, Cara Haymaker1, Michael Hurwitz3, Patrick Hwu1, Mario Sznol3, Nizar Tannir1, Anthony Conley1, Harriet Kluger3, Sandra Aung2, Michael Imperiale2, Mary Tagliaferri2, Christie Fanton2, Ernesto Iacucci2, Jonathan Zalevsky2, Ute Hoch2, Adi Diab1 1The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, 2Nektar Therapeutics, San Francisco, CA, United States of America, 3Yale School of Medicine, New Haven, CT, United States of America BACKGROUND RESULTS NKTR-214 Figure 1. NKTR-214 Mechanism of Action Figure 5. NKTR-214 induces activating markers and co-inhibitory Figure 10. Increase in T cell clonality in tumors after treatment • NKTR-214 is a CD122-biased cytokine agonist + NKTR-214 2-PEG 1-PEG receptors in proliferating CD4 T cells in peripheral blood with NKTR-214 conjugated with multiple releasable chains of (6-PEG) Active Cytokine Active Cytokine PD-1 CTLA-4 OX40 ICOS Irreversible Irreversible 15 40 20 80 5 polyethylene glycol (PEG) designed to provide Release Release • An increase in overall T cell n=11 n=15 n=9 n=15 4 (%CD4) sustained signaling through the heterodimeric + 30 60 3 (%CD4) 15 (%CD4) + (%CD4) + clonality observed in 8/12 + 10 + 2 IL-2 receptor pathway (IL-2R) to preferentially 20 1 PD-1 10 40 patients after NKTR-214 OX40 ICOS + + 10 + CTLA-4 LEGEND: + + 0 activate and expand effector CD8 T and NK 5 α Ki-67 treatment 1 NKTR-214 – Inactive 5 20 -1 Melanoma Ki67 Ki-67 5 Ki-67 + Ki-67 cells over Tregs (Figure 1).
    [Show full text]
  • BD Pharmingen™ Purified Mouse Anti-CD247 (Py142)
    BD Pharmingen™ Technical Data Sheet Purified Mouse anti-CD247 (pY142) Product Information Material Number: 558402 Alternate Name: CD3ζ Size: 0.1 mg Concentration: 0.5 mg/ml Clone: K25-407.69 Immunogen: Phosphorylated Human CD3ζ Peptide Isotype: Mouse IgG2a, κ Reactivity: QC Testing: Human Target MW: 21 kDa Storage Buffer: Aqueous buffered solution containing ≤0.09% sodium azide. Description The T cell receptor (TCR), expressed by thymocytes and T lymphocytes, is a multi-component cell-surface complex responsible for recognizing antigen in the context of MHC molecules. The antigen-specific binding component of the TCR, Ti, is a heterodimer of the variable Ig-like subunits a and b or g and d. Ti is non-covalently associated with an invariant set of molecules referred to as the CD3 polypeptides, g, d, e, and ζ. The CD3 z polypeptide (CD3z) was named CD247 at the 7th Human Leukocyte Differentiation Antigens Workshop. CD3 appears early in thymocyte differentiation and remains expressed on all mature T lymphocytes. After antigen recognition by the TCR, CD3z is the primary intracellular signal transducing subunit. It contains three ITAMs (Immunoreceptor Tyrosine-based Activation Motifs), each of which contains a pair of tyrosine residues that are phosphorylated by Lck and Fyn and are required for signal propagation. The molecular weight of CD3z is 16 kDa, and it is also observed as 32-kDa homodimers or as heterodimers with the g chain of Fc receptors. Upon phosphorylation, the CD3z monomer undergoes an apparent shift in electrophoretic mobility up to 21 kDa. The K25-407.69 monoclonal antibody recognizes the phosphorylated tyrosine 142 (pY142) in the third ITAM domain of human CD3z (CD247).
    [Show full text]